Floatz logo

Therapeutic Asset Ratings

1,045 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Locally Advanced Bladder Urothelial Carcinoma
Fred Hutchinson Cancer CenterP2BB (65)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Locally Advanced Ureter Urothelial Carcinoma
Fred Hutchinson Cancer CenterP2BB (65)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Stage IV Bladder Cancer AJCC v8
Fred Hutchinson Cancer CenterP2BB (65)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Stage IV Renal Pelvis Cancer AJCC v8
Fred Hutchinson Cancer CenterP2BB (65)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Stage IV Ureter Cancer AJCC v8
Fred Hutchinson Cancer CenterP2BB (65)
Ladiratuzumab Vedotin
Triple Negative Breast Neoplasms
Seagen Inc.P2BB (65)
Trastuzumab Deruxtecan
Triple Negative Breast Neoplasms
National Cancer Institute (NCI)P2BB (65)
Brentuximab Vedotin
Lymphoma
Chinese PLA General HospitalP4BB (64)
rc48-adc
HER2-positive Breast Cancer
Fudan UniversityP4BB (64)
Trastuzumab Deruxtecan
Breast Cancer
SWOG Cancer Research NetworkP4BB (64)
Polatuzumab Vedotin
Recurrent Diffuse Large B-Cell Lymphoma
Ruijin HospitalP3BB (64)
rc48-adc
Classical Hodgkin Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.P3BB (64)
rc48-adc
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and HospitalP3BB (64)
rc48-adc
RECTAL NEOPLASMS
Fudan UniversityP3BB (64)
Trastuzumab Deruxtecan
ER-positive Breast Cancer
Danish Breast Cancer Cooperative GroupP3BB (64)
Zilovertamab Vedotin
Diffuse Large B-cell Lymphoma
Merck Sharp & Dohme LLCP3BB (64)
Brentuximab Vedotin
Adult T-Cell Leukemia/Lymphoma
UNC Lineberger Comprehensive Cancer CenterP2BB (64)
Brentuximab Vedotin
Anaplastic Large Cell Lymphoma, ALK-Positive
New York Medical CollegeP2BB (64)
Brentuximab Vedotin
Hepato-splenic T-cell Lymphoma
Northwestern UniversityP2BB (64)
Gemtuzumab Ozogamicin
Adult Acute Monoblastic Leukemia (M5a)
National Cancer Institute (NCI)P2BB (64)
Gemtuzumab Ozogamicin
Adult Acute Monocytic Leukemia (M5b)
National Cancer Institute (NCI)P2BB (64)
Gemtuzumab Ozogamicin
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
National Cancer Institute (NCI)P2BB (64)
Gemtuzumab Ozogamicin
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Wake Forest University Health SciencesP2BB (64)
Gemtuzumab Ozogamicin
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Wake Forest University Health SciencesP2BB (64)
Gemtuzumab Ozogamicin
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Wake Forest University Health SciencesP2BB (64)
Showing 51 to 75 of 1,045 assets
PreviousPage 3 of 42Next